As major indexes climb and oil prices fluctuate, investors are turning to dividend payers for reliable income. We analyze three stocks with yields between 3% and 3.5%, examining their sustainability and growth prospects.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
The Bureau of Labor Statistics announced Monday that the highly anticipated January employment data will not be released as scheduled this Friday, citing disruptions from a partial federal government shutdown. The report will be published only after funding is restored.
In a revealing interview, former NFL quarterback Tim Tebow recounts how coach Bill Belichick asked him to decline a seven-figure endorsement deal—only to be cut days later. Yet, a decade on, Tebow expresses admiration, not bitterness, toward the legendary coach.
As the United States approaches its 250th anniversary, USA TODAY examines the enduring legacy of the companies that shaped the nation's culture, economy, and global identity.
Nvidia's journey from a niche graphics card maker to the world's most valuable company is a masterclass in technological foresight and market adaptation. This is how a bet on parallel processing powered the AI revolution.
Investment firm CapWealth Advisors has significantly increased its stake in telecom provider Lumen Technologies, signaling confidence amid the company's strategic pivot towards enterprise and AI infrastructure.
As Michelangelo's monumental fresco undergoes its first restoration in three decades, visitors to the Vatican will view a high-definition reproduction while conservators work to revive the masterpiece's original brilliance.
German biotech firm AMSilk partners with Italian mill Pure Denim to launch a new category of high-performance, sustainable denim infused with lab-grown spider silk proteins, targeting the luxury market with enhanced comfort and eco-credentials.
If confirmed, incoming Fed Chair Kevin Warsh will inherit a booming yet bifurcated economy. Despite strong GDP growth and a surging stock market, stagnant hiring and sinking consumer confidence present a policy puzzle where interest rate cuts may offer no easy fix.
Real estate mogul Grant Cardone has ignited a fierce debate by labeling credit scores a system designed to perpetuate debt, arguing true wealth is built on assets that bypass traditional credit checks. The controversial claim has drawn both support from anti-debt figures and sharp criticism from those who see it as out-of-touch advice for the average earner.
Shareholders in Harley-Davidson's electric motorcycle spinoff, LiveWire Group, have seen their holdings erode dramatically over five years, with a recent $55 million weekly loss adding to the pain. The company's ongoing revenue contraction raises fundamental questions about its path to profitability in the competitive EV market.
A Foxboro woman's two-year struggle with a defective high-end oven underscores the enduring power of state consumer protection laws, even after a manufacturer's warranty expires.
Meta Platforms' relentless investment in artificial intelligence infrastructure is set to drive capital expenditures to unprecedented levels in 2026, raising questions about long-term returns for the cash-rich tech giant.
The U.S. Securities and Exchange Commission has ushered in a new era for the accounting watchdog, naming a fresh chair and three board members tasked with refocusing the PCAOB on its core mission of investor protection.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Two French infant formula makers have recalled multiple product batches following the government's decision to slash permissible levels of cereulide, a toxin linked to gastrointestinal illness. The move amplifies a global safety crisis that has seen major brands issue recalls across dozens of countries since late last year.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
